Early Convalescent Plasma May Not Prevent Disease Progression Among High-Risk Outpatients With COVID-19, Study Finds

Healio (8/18, Southall) reports, “COVID-19 convalescent plasma administered within 7 days of symptom onset did not appear to prevent disease progression among high-risk outpatients with COVID-19, according to” results published in The New England Journal...